Sales in UK expected to be followed by launches across major EU territories in 2022 Loughborough, England, Dec. 07,...
Loughborough, England, Nov. 03, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing...
MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England,...
Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up Loughborough, England – September 27, 2021...
Loughborough, England – September 21, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...
Loughborough, England – September 17, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology...
Loughborough, England – September 1, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...
Loughborough, England – August 16, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England – July 12, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on...
Loughborough, England – June 30, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...